TROMBOTIČNA MIKROANGIOPATIJA KAO PRVA MANIFESTACIJA DISEMINOVANE MALIGNE BOLESTI

Željko Todorović; Marko Anđelić

doi:10.5937/smclk3-40946

Željko Todorović
Marko Anđelić

DOI: https://doi.org/10.5937/smclk3-40946

Ključne reči: trombotična mikroangiopatija, trombotična trombocitopenijska purpura, hemolitičko-uremijski sindrom

Sažetak

Uvod: Trombotične mikroangiopatije su grupa bolesti koje karakterišu diseminovana intravaskularna tromboza, trombocitopenija i ishemijsko oštećenje organa. U ovu grupu spadaju trombotična trombocitopenijska purpura i hemolitičko-uremijski sindrom. Mada retko, jedan od uzroka trombotične mikroangiopatije mogu biti i maligne bolesti, pre svega karcinomi želuca, prostate, dojke i pluća.

Prikaz bolesnika: Prikazujemo pacijentkinju sa trombotičnom mikroangiopatijom i diseminovanom malignom bolešču nejasne etiologije.

Zaključak: Ovaj klinički entitet se naziva trombotična mikroangiopatija udružena sa tumorima. Prvi put je opisana 1970. godine, ali je do danas opisano svega nekoliko desetina slučajeva. S obzirom na veliku smrtnost, treba misliti o njemu kod pacijenata sa malignom bolešču, prisutnom mikroangiopatskom hemoliznom anemijom i trombocitopenijom.

Reference

1. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017 Jan 30;189(4):E153-E159. doi: 10.1503/cmaj.160142.

2. Said A, Haddad RY, Stein R, Lerma EV. Thrombotic thrombocytopenic purpura. Dis Mon. 2014 Oct;60(10):500-4. doi: 10.1016/j.disamonth.2014.08.005.

3. Corrigan JJ Jr, Boineau FG. Hemolytic-uremic syndrome. Pediatr Rev. 2001 Nov;22(11):365-9.

4. Brain MC, Azzopardi JG, Baker LR, Pineo GF, Roberts PD, Dacie JV. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol. 1970 Feb;18(2):183-93. doi: 10.1111/j.1365-2141.1970.tb01433.x.

5. Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016 Jun 28;10:649. doi: 10.3332/ecancer.2016.649.

6. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012 Jul;91(4):195-205. doi: 10.1097/MD.0b013e3182603598.

7. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:292-9. doi: 10.1182/asheducation-2013.1.292.

8. Otrock ZK, Taher AT, Makarem JA, Kattar MM, Nsouli G, Shamseddine AI. Thrombotic thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer. Dig Dis Sci. 2007 Jun;52(6):1589-91. doi: 10.1007/s10620-006-9407-7.

9. Rauh MJ, Al Habeeb A, Chang H. Microangiopathic hemolytic anemia and leukoerythroblastic blood film heralding bone marrow metastatic gastroesophageal adenocarcinoma. Pathol Res Pract. 2011 Feb 15;207(2):121-3. doi: 10.1016/j.prp.2010.07.003.

10. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N, Billemont B, Deray G. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006 Nov;21(11):3038-45. doi: 10.1093/ndt/gfl507.

11. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008 Jun;87(6):495-6. doi: 10.1007/s00277-007-0429-9.

12. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24(7):491-501. doi: 10.2165/00002018-200124070-00002.

13. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985 Jan 1;55(1):47-50. doi: 10.1002/1097-0142(19850101)55:1<47::aid-cncr2820550108>3.0.co;2-#.